Effect of Bacopa Monnieri on Working Memory and Cognitive Processing in Student

August 15, 2017 updated by: Jintanaporn Wattanathorn, Khon Kaen University
The purpose of this study is to determine the effect of Bacopa Monnieri on working memory and cognitive processing in student.

Study Overview

Detailed Description

Learning and working memory are two of the key role for studying and work successful for student particular the high school student who study hard and preparing themselves for the graduate study. The consumption of brain booster product or functional food for improving memory has gained much attention. It has been reported that Bacopa Monnieri could improve learning and working memory in elderly subject by improving the N100 and P300 event related potential. Therefore, Bacopa Monnieri might be the potential product for improving the learning and working memory in student particular high school student.

Study Type

Interventional

Enrollment (Actual)

75

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Khon Kaen, Thailand, 40002
        • Jitanaporn Wattanathorn

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

11 years to 14 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy student subject aged between 15-18 years old who studying in the school within Khon Kaen province.
  • Body mass index is between 18.5-24.9

Exclusion Criteria:

  • Subjects who are diagnosed with one of the following: cardiovascular diseases, respiratory disease, neuropsychological diseases, head injury, diabetes mellitus, liver disease, cancer, autoimmune disease and hematological disorder are excluded.
  • Subjects who take any medicine or nutraceuticals or hormone that effect on central nervous system are excluded.
  • Alcohol addict or smoking addiction (more than 10 pieces/day)
  • Athlete or subjects who have a regular exercise more than 3 times/week
  • Subjects who don't follow the instruction during the trial
  • Subjects who are participating the other project.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Subjects are received the pill of placebo which has same color, shape and smell like the Bacopa Monnieri once daily for 16 weeks.
Subjects are received Placebo once daily for 16 weeks.
Active Comparator: Bacopa Monnieri 300 mg/day
Subjects are received the pill of Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks
Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.
Active Comparator: Bacopa Monnieri 600 mg/day
Subjects are received the pill of Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks
Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive processing using the latency of P300 wave
Time Frame: 4 months
The latency of P300 wave was measured and expressed as millisecond.
4 months
Cognitive processing using the amplitude of P300 wave
Time Frame: 4 months
The amplitude of P300 wave was measured and expressed as micro-volt.
4 months
Attention using the latency of N100 wave
Time Frame: 4 months
The latency of N100 wave was measured and expressed as millisecond.
4 months
Attention using the amplitude of N100 wave
Time Frame: 4 months
The amplitude of N100 wave was measured and expressed as micro-volt.
4 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Accuracy of working memory using computerized battery test
Time Frame: 4 months
The accuracy of working memory was determined and expressed as percentage.
4 months
Speed of working memory using computerized battery test
Time Frame: 4 months
The speed of working memory was determined and expressed as millisecond.
4 months
Assessment of psychiatric symptoms using the symptom check list 90 (SCL-90)
Time Frame: 4 months
4 months
Assessment of mood scale using Bond-Lader visual analogue scales
Time Frame: 4 months
4 months
Acetylcholinesterase activity in serum
Time Frame: 4 months
4 months
Monoamine oxidase activity in serum
Time Frame: 4 months
4 months
Glutamic acid decarboxylase (GAD) activity in serum
Time Frame: 4 months
4 months
Gamma-aminobutyric acid (GABA)-transaminase in serum
Time Frame: 4 months
4 months
Malondialdehyde level in serum
Time Frame: 4 months
4 months
Activity of superoxide dismutase in serum
Time Frame: 4 month
4 month
Activity of catalase in serum
Time Frame: 4 month
4 month
Activity of glutathione peroxidase in serum
Time Frame: 4 month
4 month
Consumption safety of Bacopa Monnieri using electrocardiogram (EKG)
Time Frame: 4 month
4 month
Consumption safety of Bacopa Monnieri using hematological values .
Time Frame: 4 month
The hematological values including red blood cell, white blood cell, hematocrit and platelet were determined and the data was expressed as number of subject presented with abnormal hematological value.
4 month
Consumption safety of Bacopa Monnieri using blood chemistry
Time Frame: 4 month
The blood chemistry values including renal function test, liver function test, lipid profile, electrolytes and glucose were determined and the data was expressed as number of subject presented with abnormal blood chemistry value.
4 month
Consumption safety of Bacopa Monnieri using blood pressure measurement
Time Frame: 4 month
4 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2016

Primary Completion (Actual)

March 1, 2017

Study Completion (Actual)

March 1, 2017

Study Registration Dates

First Submitted

October 8, 2016

First Submitted That Met QC Criteria

October 11, 2016

First Posted (Estimate)

October 13, 2016

Study Record Updates

Last Update Posted (Actual)

August 18, 2017

Last Update Submitted That Met QC Criteria

August 15, 2017

Last Verified

August 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • HE581418

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Placebo

Subscribe